The Taiho and Eli Lilly-backed immunotherapy developer floated in the middle of its range to raise $75.6m, valuing it at about $334m.
Harpoon Therapeutics, a US-based immuno-oncology drug developer that counts pharmaceutical firms Eli Lilly and Taiho as investors, floated on Friday in a $75.6m initial public offering.
The offering consisted of 5.4 million shares issued on the Nasdaq Global Select Market and priced at $14 each, in the middle of its $13 to $15 range, valuing the company at approximately $334m. They debuted at $14.00 each on Friday before closing at $13.50.
Founded in 2015, Harpoon is developing T cell…
